Company intelligence / Profile preview

Rafael Holdings

Newark, New Jersey, United Statesrafaelholdings.com ↗

Ownership: Public · RFL
Development stage: Phase 3

Overview

Rafael Holdings’ lead clinical asset, Trappsol® Cyclo™, developed by its subsidiary Cyclo Therapeutics, is currently being evaluated in a Phase III trial for the treatment of Niemann-Pick Disease Type C1. The company also holds interests in oncology therapeutics focused on cancer metabolism and has additional early-stage/preclinical programs through subsidiaries and investments.

Therapeutic areas: OtherOncologyRare Diseases
Modalities: Small molecules (oncology therapeutics)Cyclodextrin-based therapies (via Cyclo Therapeutics/Trappsol Cyclo)Medical devices (orthopedic instruments via Rafael Medical Devices)
Industry: Biotech

Drug pipeline

1 asset

SHIN1

Preclinical

Financials

Market cap: $117.3M
Total revenue: $179K
Enterprise value: $87.4M

Beyond the preview

Go deeper on Rafael Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rafael Holdings.

Explore the full profile